Medicine company Novartis (NVS) said on Thursday that a late-stage trial evaluating its drug Cosentyx in adults with newly diagnosed or relapsing giant cell arteritis failed to meet its primary goal ...

Choose San Francisco Business Times as a preferred news source to see more of our reporting on Google. His company has less than $26.3 million now and is ending work on its rare-disease treatment.

A common diabetes medication does not help people with peripheral artery disease (PAD) and without diabetes walk farther, ...

Drug maker Novo Nordisk says semaglutide, the active ingredient for the weight loss jab Wegovy, does not slow Alzheimer's - despite initial hopes that it might help against dementia. Researchers began ...

Established drugs were repurposed, “me-too” drugs were approved, and even the few new biological approaches lacked clinical ...

A malaria drug President Donald Trump took to try to prevent COVID-19 proved ineffective for that in the first large, high-quality study to test it in health workers and others closely exposed to ...

Dec 11 (Reuters) - Rezolute said ‌on Thursday ‌its experimental drug for ⁠a ‌rare condition that ‍causes dangerously low blood ‌sugar failed to meet the main ⁠goal in a late-stage study. (Reporting by ...

TRENTON, N.J. (AP) -- A closely watched experimental Alzheimer's treatment has failed to slow the disease in one late-stage study, a big disappointment for doctors and patients but not the end of the ...